Thanks to the artificial intelligence (AI) boom, a resilient U.S. economy, and falling interest rates, membership in the club isn't quite ... Costco's P/E of 57. Eli Lilly (NYSE: LLY) is now ...

Last week, on Dec. 13, this elite club welcomed its newest member ... Likewise, drugmaker Eli Lilly is expected to face growing competition in the weight-loss category. And while President ...

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this. On rare occasions, our expert team of analysts issues a “Double Down” stock ...

This year's developments in the obesity market have really gone in Eli Lilly’s (NYSE:LLY) favor. Clinical trial results from competitors were largely underwhelming, including this week’s ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,146.00. The company’s shares closed ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Eli Lilly, the world’s largest drugmaker by market value, is in advanced talks to buy cancer-focused ...

Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target remains the same with $1,100.00. Discover the latest ...

Eli Lilly's biggest catalyst at the moment comes from its hit weight loss medications, Mounjaro and Zepbound. Lilly is investing billions of dollars to scale manufacturing efforts as demand for ...

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

On Dec. 9, healthcare giant Eli Lilly announced the approval of a new $15 billion share buyback program and yet another significant dividend increase. For a seventh consecutive year, the company ...